AR088075A1 - Derivados de mostaza de nitrogeno - Google Patents
Derivados de mostaza de nitrogenoInfo
- Publication number
- AR088075A1 AR088075A1 ARP120103588A ARP120103588A AR088075A1 AR 088075 A1 AR088075 A1 AR 088075A1 AR P120103588 A ARP120103588 A AR P120103588A AR P120103588 A ARP120103588 A AR P120103588A AR 088075 A1 AR088075 A1 AR 088075A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- nrcrd
- orb
- srb
- halo
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Reproductive Health (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Transplantation (AREA)
- Pregnancy & Childbirth (AREA)
- Psychiatry (AREA)
- Gastroenterology & Hepatology (AREA)
- Obesity (AREA)
- Oncology (AREA)
- Gynecology & Obstetrics (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
Se describe el compuesto de la formula (1). También se describe un método para tratar una enfermedad neoplásica o una enfermedad inmunitaria con estos compuestos. Reivindicación 1: Un compuesto de fórmula (1) caracterizado porque: cada uno de X¹ y X² independientemente, es halo o OSO₂Rᵃ, donde Rᵃ es alquilo, alquenilo o alquinilo; Q es cicloalquilo, cicloalquenilo, heterocicloalquenilo, arilo o heteroarilo, cada uno de los cuales, independientemente, está opcionalmente sustituido por alquilo, alquenilo, alquinilo, cicloalquilo, heterocicloalquilo, cicloalquenilo, heterocicloalquenilo, arilo, heteroarilo, halo, nitro, oxo, -CH=NH, ciano, alquil-Rᵇ, CH=NORᵇ, ORᵇ, OC(O)Rᵇ, OC(O)ORᵇ, OC(O)SRᵇ, SRᵇ, C(O)Rᵇ, C(O)ORᵇ, C(O)SRᵇ, C(O)NRᶜRᵈ, SORᵇ, SO₂Rᵇ, NRᶜRᵈ, alquil-NRᶜRᵈ o N(Rᶜ)C(O)Rᵈ, donde cada uno de Rᵇ, Rᶜ y Rᵈ, independientemente, es H, alquilo, alquenilo, alquinilo, cicloalquilo, heterocicloalquilo, arilo, heteroarilo, halo, ciano, nitro, amino, hidroxilo, alquilamino, haloalquilo o alcoxi; Z se elimina o es (CH₂)ₘ donde m es un entero de 1 a 10; y cada uno de R¹ y R² independientemente, es H, alquilo, alquenilo, alquinilo, cicloalquilo, heterocicloalquilo, cicloalquenilo, heterocicloalquenilo, arilo, heteroarilo, halo, nitro, oxo, -CH=NH, ciano, alquil-Rᵇ, CH=NORᵇ, ORᵇ, OC(O)Rᵇ, OC(O)ORᵇ, OC(O)SRᵇ, SRᵇ, C(O)Rᵇ, C(O)ORᵇ, C(O)SRᵇ, C(O)NRᶜRᵈ, SORᵇ, SO₂Rᵇ, NRᶜRᵈ, alquil-NRᶜRᵈ o N(Rᶜ)C(O)Rᵈ.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161540523P | 2011-09-28 | 2011-09-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR088075A1 true AR088075A1 (es) | 2014-05-07 |
Family
ID=47996730
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP120103588A AR088075A1 (es) | 2011-09-28 | 2012-09-27 | Derivados de mostaza de nitrogeno |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US8962855B2 (es) |
| EP (1) | EP2760860B8 (es) |
| JP (1) | JP6008972B2 (es) |
| AR (1) | AR088075A1 (es) |
| AU (1) | AU2012316084B2 (es) |
| CA (1) | CA2850541C (es) |
| CY (1) | CY1118626T1 (es) |
| DK (1) | DK2760860T3 (es) |
| ES (1) | ES2616242T3 (es) |
| HR (1) | HRP20170196T1 (es) |
| HU (1) | HUE031445T2 (es) |
| IL (1) | IL231170A (es) |
| LT (1) | LT2760860T (es) |
| MX (1) | MX342746B (es) |
| PL (1) | PL2760860T3 (es) |
| PT (1) | PT2760860T (es) |
| RS (1) | RS55680B1 (es) |
| SI (1) | SI2760860T1 (es) |
| SM (1) | SMT201700108B (es) |
| TW (1) | TW201326162A (es) |
| WO (1) | WO2013049279A2 (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9180127B2 (en) | 2009-12-29 | 2015-11-10 | Dana-Farber Cancer Institute, Inc. | Type II Raf kinase inhibitors |
| TWI573792B (zh) | 2012-02-01 | 2017-03-11 | 歐陸斯迪公司 | 新穎治療劑 |
| EP3078671A4 (en) * | 2013-12-04 | 2017-05-31 | Hangzhou Minsheng Institutes for Pharma Research Co., Ltd. | Gemcitabine derivative, composition containing the derivative and pharmaceutical use of the derivative |
| EP3125920B1 (en) | 2014-04-04 | 2020-12-23 | Del Mar Pharmaceuticals | Dianhydrogalactitol, diacetyldianhydrogalactitol or dibromodulcitol to treat non-small-cell carcinoma of the lung and ovarian cancer |
| GB201409485D0 (en) | 2014-05-28 | 2014-07-09 | Euro Celtique Sa | Pharmaceutical composition |
| GB201409471D0 (en) | 2014-05-28 | 2014-07-09 | Euro Celtique Sa | Pharmaceutical composition |
| GB201409488D0 (en) | 2014-05-28 | 2014-07-09 | Euro Celtique Sa | Pharmaceutical composition |
| CA2996978A1 (en) * | 2015-09-09 | 2017-03-16 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinases |
| AU2016426574B2 (en) | 2016-10-11 | 2023-07-13 | Euro-Celtique S.A. | Hodgkin lymphoma therapy |
| GB201709402D0 (en) | 2017-06-13 | 2017-07-26 | Euro Celtique Sa | Compounds for treating t-pll |
| GB201709406D0 (en) | 2017-06-13 | 2017-07-26 | Euro-Cletique S A | Compounds for treating TNBC |
| GB201709405D0 (en) | 2017-06-13 | 2017-07-26 | Euro Celtique Sa | Compounds for treating ovarian cancer |
| GB201709403D0 (en) | 2017-06-13 | 2017-07-26 | Euro Celtique Sa | Compounds for treating sarcoma |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5882941A (en) * | 1994-05-04 | 1999-03-16 | Massachusette Institute Of Technology | Programmable genotoxic agents and uses therefor |
| US6214852B1 (en) * | 1998-10-21 | 2001-04-10 | Bristol-Myers Squibb Company | N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases |
| US6392053B2 (en) * | 1999-12-15 | 2002-05-21 | Bristol-Myers Squibb Company | Process for preparing arylacetylaminothiazoles |
| EP2061772A4 (en) * | 2006-09-11 | 2011-06-29 | Curis Inc | MULTIFUNCTIONAL SMALL MOLECULES AS PROLIFERATION-ACTIVE ACTIVE SUBSTANCES |
| TW200922564A (en) * | 2007-09-10 | 2009-06-01 | Curis Inc | CDK inhibitors containing a zinc binding moiety |
| US8309554B2 (en) * | 2008-05-15 | 2012-11-13 | Threshold Pharmaceuticals | Hypoxia activated drugs of nitrogen mustard alkylators |
| WO2010075542A1 (en) * | 2008-12-23 | 2010-07-01 | Curis, Inc. | Cdk inhibitors |
-
2012
- 2012-09-27 PT PT128369865T patent/PT2760860T/pt unknown
- 2012-09-27 AU AU2012316084A patent/AU2012316084B2/en active Active
- 2012-09-27 TW TW101135740A patent/TW201326162A/zh unknown
- 2012-09-27 AR ARP120103588A patent/AR088075A1/es not_active Application Discontinuation
- 2012-09-27 LT LTEP12836986.5T patent/LT2760860T/lt unknown
- 2012-09-27 ES ES12836986.5T patent/ES2616242T3/es active Active
- 2012-09-27 SI SI201230831A patent/SI2760860T1/sl unknown
- 2012-09-27 EP EP12836986.5A patent/EP2760860B8/en active Active
- 2012-09-27 JP JP2014533702A patent/JP6008972B2/ja active Active
- 2012-09-27 MX MX2014003839A patent/MX342746B/es active IP Right Grant
- 2012-09-27 DK DK12836986.5T patent/DK2760860T3/en active
- 2012-09-27 CA CA2850541A patent/CA2850541C/en active Active
- 2012-09-27 US US14/347,397 patent/US8962855B2/en active Active
- 2012-09-27 PL PL12836986T patent/PL2760860T3/pl unknown
- 2012-09-27 RS RS20170167A patent/RS55680B1/sr unknown
- 2012-09-27 HU HUE12836986A patent/HUE031445T2/en unknown
- 2012-09-27 WO PCT/US2012/057445 patent/WO2013049279A2/en active Application Filing
-
2014
- 2014-02-26 IL IL231170A patent/IL231170A/en active IP Right Grant
-
2017
- 2017-02-07 HR HRP20170196TT patent/HRP20170196T1/hr unknown
- 2017-02-10 CY CY20171100187T patent/CY1118626T1/el unknown
- 2017-02-16 SM SM201700108T patent/SMT201700108B/it unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2014528003A (ja) | 2014-10-23 |
| US20140303218A1 (en) | 2014-10-09 |
| HRP20170196T1 (hr) | 2017-04-07 |
| EP2760860A2 (en) | 2014-08-06 |
| WO2013049279A3 (en) | 2013-07-18 |
| MX342746B (es) | 2016-10-11 |
| IL231170A (en) | 2015-07-30 |
| IL231170A0 (en) | 2014-04-30 |
| DK2760860T3 (en) | 2017-02-27 |
| AU2012316084B2 (en) | 2016-10-27 |
| CA2850541C (en) | 2019-11-05 |
| RS55680B1 (sr) | 2017-07-31 |
| EP2760860B1 (en) | 2016-11-16 |
| SMT201700108B (it) | 2017-03-08 |
| AU2012316084A1 (en) | 2014-03-20 |
| ES2616242T3 (es) | 2017-06-12 |
| SI2760860T1 (sl) | 2017-04-26 |
| EP2760860A4 (en) | 2015-04-22 |
| EP2760860B8 (en) | 2017-03-08 |
| WO2013049279A2 (en) | 2013-04-04 |
| PT2760860T (pt) | 2017-02-21 |
| JP6008972B2 (ja) | 2016-10-19 |
| CY1118626T1 (el) | 2017-07-12 |
| US8962855B2 (en) | 2015-02-24 |
| HUE031445T2 (en) | 2017-07-28 |
| PL2760860T3 (pl) | 2017-06-30 |
| MX2014003839A (es) | 2015-01-16 |
| TW201326162A (zh) | 2013-07-01 |
| LT2760860T (lt) | 2017-03-10 |
| CA2850541A1 (en) | 2013-04-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR088075A1 (es) | Derivados de mostaza de nitrogeno | |
| AR087909A1 (es) | Composiciones farmaceuticas | |
| AR089527A1 (es) | Inhibidores de bromodominios | |
| IN2014CN01136A (es) | ||
| AR098872A1 (es) | Moduladores de tetrahidropiridopirazinas de gpr6 | |
| PE20220507A1 (es) | Compuestos utiles como inhibidores de cinasa | |
| AR088175A1 (es) | 3-pirimidin-4-il-oxazolidin-2-onas utiles para tratar cancer y composiciones farmaceuticas que las contienen | |
| AR101815A1 (es) | Compuestos y composiciones como inhibidores de quinasa | |
| AR108245A1 (es) | Síntesis de indazoles | |
| AR080057A1 (es) | Piridinas disustituidas como anticancerigenos | |
| EA200870191A1 (ru) | Новые производные циклической мочевины, их получение и фармацевтическое применение в качестве ингибиторов киназ | |
| PH12015500008A1 (en) | Dimethyl-benzoic acid compounds | |
| WO2010005534A3 (en) | Proteasome inhibitors for selectively inducing apoptosis in cancer cells | |
| AR100807A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| EA201690879A1 (ru) | Новое триазолопиридиновое соединение | |
| ES2526902T3 (es) | Procesos de producción de inhibidores de la girasa y topoisomerasa IV | |
| RU2021109549A (ru) | ИНГИБИТОРЫ α-АМИНО-β-КАРБОКСИМУКОНАТ ε-СЕМИАЛЬДЕГИД-ДЕКАРБОКСИЛАЗЫ | |
| AR093758A1 (es) | Inhibidores de aril lactama quinasa | |
| AR087503A1 (es) | Polisulfuros reticulados de organosilicio | |
| AR098270A1 (es) | Poliéster terminado en epoxi | |
| MX2016017405A (es) | Compuestos derivados de 2-(3-piridinil)-1h-benzimidazol y medicamentos que los contienen. | |
| AR106047A1 (es) | Derivado de biarilo y medicamento que contiene el mismo para el tratamiento de infecciones fúngicas | |
| AR101222A1 (es) | Derivados de piridona | |
| AR093128A1 (es) | Inhibidores de la syk | |
| EA201790468A1 (ru) | Биосвязующее |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |